校閲サンプル

原文

Fingolimod (FTY720) has shown its effectiveness in decreasing relapses among the Caucasian population with MS.

Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported.

The patient was prescribed FTY720 1.25 mg once-daily for the past three years. Regular MRI and Gd-enhanced MRI examination was done every three months.

続きを見る

For the above described observational period, the patient has been free of Gd-enhanced lesions, indicating favorable result from fingolimod. Adverse events related to FTY720 included liver enzyme levels, and the increased cases of minor palpitations. Although its relationship to the use to FTY720 is yet unknown, the other event reported includes worsening of past symptoms from the past exacerbations, such as persisting numbness and pain in the limbs, headaches, taste disorder.

This case demonstrated the clinical efficacy of fingolimod in reducing relapses in remitting MS patient, consistent with the established effects of fingolimod in Caucasian patients. However, this study indicated the further needs to study the cause and the mechanisms of adverse effects that may not seem directly related to use of FTY720.

閉じる

プレミアム校閲

プレミアム校閲では、原文のスタイルを残した上で、文法・言い回し・単語の選択・ロジックなどを査読経験や論文執筆経験豊富な欧米のネイティブ校閲者が校閲します。

Fingolimod (FTY720) has shown its effectiveness in decreasing relapses among the Caucasian population with MS.(NOTE: I would suggest changing the underlined sentence to, “Fingolimod (FTY720) was shown to be effective in reducing relapses in patients with multiple sclerosis (MS) in the Caucasian population.”)

Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported. (NOTE: How do you think about changing the underlined sentence to, “We report the efficacy and safety of FTY720 in a 38-year-old, Japanese female patient with relapsing MS who was treated with FTY720 for the past 3 years.”?

The patient was prescribed FTY720 1.25 mg once-daily for the past three years. Regular MRI and Gd-enhanced MRI examinations were performed every three months.

続きを見る

During the three-year observation period, the patient has not had Gd-enhanced lesions, indicating a favorable result from fingolimod. Adverse events included increased liver enzyme levels and the increased occurrences of minor heart palpitations. Although its relationship to the use to FTY720 is yet unknown, the Other reported adverse events of FTY720 include worsening of symptoms from past exacerbations, such as persistent numbness and pain in the limbs, headaches, and taste disorder.

This case demonstrated the clinical efficacy of fingolimod in reducing relapses in a relapsing-remitting Japanese MS patient, consistent with the established effects of fingolimod in Caucasian patients. However, this study indicated the further needs to study the cause and the mechanisms of adverse effects that may not seem directly related to use of FTY720. (NOTE: How do you think about changing the underlined sentence to, “However, further studies with a greater number of MS patients are needed to study the cause and mechanisms of adverse effects that may not be directly related to the use of FTY720.”?)

閉じる

原文を最大限に尊重しながらも、より読みやすく明瞭な英文となるように仕上げます。
※プレミアム校閲は変更履歴及びコメント機能を使用した校閲も可能です。その際には、上記のNOTE部分はコメント機能を使用し挿入いたします。

プレミアムEX校閲

プレミアムEX校閲では、プレミアム校閲の校閲に加え、原文のスタイルを残しながらも大幅に書き直す作業を行います。必要に応じて、文の結合や分離等のご提案をさせていただきます。

Fingolimod (FTY720) is effective in reducing relapses among the Caucasian population in a patient with MS. (Note: I suggest deleting the word "Caucasian" since there is no comparison to non-Caucasian patients.)

Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported. (Note: I suggest changing the underlined to "Here, we report the efficacy of treatment and the safety outcome of a patient (female, 38 years old) with relapsing multiple sclerosis (MS) who was treated with fingolimod (FTY720) for the past three years".)

The patient was administered FTY720 (1.25 mg, q.d.) for the past three years. Regular MRI and Gd-enhanced MRI was performed every three months.

続きを見る

During the observational period, the patient did not show Gd-enhanced lesions, which indicated a favorable result from fingolimod FTY720. (Note: Drug names should be consistent throughout the text.) Adverse events related to FTY720 included liver enzyme levels (Note: High or low?), and increased incidence of minor heart palpitations. Although its relationship to the use to FTY720 is yet unknown, Other events reported includes a worsening of past symptoms from the past exacerbations, such as persisting numbness and pain in the limbs, headaches, and taste disorder, although the relationship of these symptoms to the use of FTY720 is unclear.

This case demonstrates the clinical efficacy of FTY720 in reducing relapses in remitting MS patient, consistent with the established effects of FTY720 in Caucasian MS patients. (Note: In the results paragraph, there was no mention of the efficacy of FTY720 in reducing relapses. I suggest adding this result.) However, further study is needed to clarify the cause and the mechanisms of adverse effects that have not been attributed directly to the use of FTY720.

閉じる

※プレミアムEX校閲は変更履歴及びコメント機能を使用した校閲も可能です。その際には、上記のNOTE部分はコメント機能を使用し挿入いたします。

フルチェンジリライト

フルチェンジリライトでは、ネイティブの英語と同等な英文に仕上げるため、文法・語彙選択・論文内容の校閲にとどまらず、原文のスタイルや構成等を根本的に書き換えるリライトを行います。

原文

Fingolimod (FTY720) has shown its effectiveness in decreasing relapses among the Caucasian population with MS.

Efficacy and safety outcome of past three years in a 38 year old female patient with relapsing MS treated with FTY720 is reported.

The patient was prescribed FTY720 1.25 mg once-daily for the past three years. Regular MRI and Gd-enhanced MRI examination was done every three months.

続きを見る

For the above described observational period, the patient has been free of Gd-enhanced lesions, indicating favorable result from fingolimod. Adverse events related to FTY720 included liver enzyme levels, and the increased cases of minor palpitations. Although its relationship to the use to FTY720 is yet unknown, the other event reported includes worsening of past symptoms from the past exacerbations, such as persisting numbness and pain in the limbs, headaches, taste disorder.

This case demonstrated the clinical efficacy of fingolimod in reducing relapses in remitting MS patient, consistent with the established effects of fingolimod in Caucasian patients. However, this study indicated the further needs to study the cause and the mechanisms of adverse effects that may not seem directly related to use of FTY720.

閉じる

依頼内容

専用依頼フォームで以下の項目等を確認いたします。

  • スペル:米国・英国・どちらでも可
  • 動詞:受動態・能動態 → 状況に合わせて選択して欲しい。
  • 一人称代名詞: I・We
  • 原稿のスタイル変更度合い:しっかり・適度に
  • 言い回しまたは単語の変更度合い:しっかり・適度に
  • 原稿の流れに対する変更度合い:しっかり・適度に
  • 投稿規定と照合:希望する(+20%追加料金発生)

納品原稿

Purpose: Fingolimod (FTY720; trade name Gilenya, Novartis) is a sphingosine-1-phosphate structural analogue used to prevent autoimmune reactions. It has been shown to decrease relapses among the Caucasian population with multiple sclerosis (MS). The purpose of this study was to determine the efficacy and safety of FTY720, for a prior three year treatment period, in a 38-year-old female patient with relapsing MS.

Methods: The patient was prescribed FTY720 at 1.25 mg/day for three years prior. Routine magnetic resonance imaging (MRI) and gadolinium-enhanced MRIs were conducted on the patient every three months.

続きを見る

Results: For the observational period of three years, the patient was free of lesions, indicating favorable results from fingolimod treatments. Adverse events related to FTY720 included increased liver enzyme levels, and increased episodes of minor palpitations. Additional symptoms which may not be related to FTY720 treatments included worsening of past symptoms, such as persistent numbness and pain in the limbs, headaches, taste disorders.

Conclusions: This case study demonstrated clinical efficacy of fingolimod for reducing relapses in a remitting MS patient. The result was in agreement with the reported effects of fingolimod treatments in Caucasian patients with MS. Further studies should be done to determine the cause and the mechanism of the adverse effects that may or may not be related to the use of FTY720.

閉じる

※実際の納品原稿は修正履歴及びコメント機能と使用した修正が挿入されておりますが、ここでは原文からの書き換えを分かりやすくするため、修正箇所を表示しておりません。

日本人科学翻訳者による校閲前下準備サポート

日本人科学翻訳者による校閲前下準備サポートは、校閲前の英文を構築する段階で、日本人科学翻訳者に対して、英語の表現方法等に関する質問や不明点を、日本語で確認することができます。多くの学術文書の翻訳経験を持つ翻訳者とともに英文を作り上げた後、校閲者によって英文法の最終的な校閲(カジュアル校正)を行います。※プレミアム校閲に変更することも可能です。

依頼原稿

納品原稿

翻訳者からの納品原稿

翻訳者からの納品原稿

カジュアル校正後納品原稿

納品原稿
校閲サンプル トップ
ご依頼はこちら

最短1時間でお見積り!

お見積り・正式発注はこちら
はじめてのお客様はじめてのお客様

初回割引または無料トライアルから!

はじめてのお客様は初回割引または無料トライアルのサービス

お電話でのお問い合わせはこちら営業時間.平日 9:30~18:00

Tel.045-290-7200